Biotech Daily Market Report September 22, 2006
September 22nd 2006 07:06
ASX DOWN, BIOTECHS EVEN:
COGSTATE UP 15%
CYGENICS, POLARTECHNICS DOWN 9%
THE MARKET
The Australian stock market fell 0.22 percent on Friday September 22, 2006, with the All Ordinaries down 11.0 points to 4,948.4 points. Fourteen of the Biotech Daily Top 40 stocks were up, 14 stocks fell, nine traded unchanged and three were untraded. Seven of the Top 20 rose and eight fell, while seven of the Second 20 rose and six stocks fell.
Cogstate was best up 3.5 cents or 14.89 percent to 27 cents on low volumes, followed by Agenix up one cent or 7.14 percent to 15 cents and Bionomics up one cent or 6.54 percent to 16.5 cents. Psivida climbed 5.08 percent, Progen was up 4.35 percent and Sirtex climbed 3.52 percent. Metabolic and Uscom were up more than two percent, with Chemgenex, CSL and Prima up more than one percent.
Cygenics led the falls, down 2.5 cents or 9.09 percent to 25 cents with Polartechnics also down 9.09 percent losing one cent to 10 cents and Optiscan down 2.5 cents or 5.26 percent to 45 cents. Living Cell, Neuren and Portland fell more than four percent; Alchemia and Phylogica lost more than three percent; Cytopia and Peplin fell more than two percent; with Clinical Cell and Phosphagenics losing more than one percent.
TODAY'S NEWS
* PHYLOGICA’S PHYLOMER LIBRARY EXPANDS 400%
* GIACONDA SIGNS SECOND EURO-INTENT
* NEUREN OFFERS $1.5m SHARE PLAN
* VIRAX IN $4.1m RIGHTS ISSUE
* COGSTATE AGM CONSIDERS 47% HIKE IN DIRECTORS FEES
* BIODIEM APPOINTS DR JOHN BROWN DIRECTOR
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 38 |
| Vote |
Add To: 
subscribe to this blog